Mandate

Vinge advises owner in connection with sale of Kung Markatta

May 06, 2013

Vinge has advised Ekomodern F, W & E AB in connection with the sale of Kung Markatta AB to Priveq Investment Fund IV. The company’s current indirect owners, i.e. Peter Enberg, Stefan Wilhelmson and CEO Anders Dahlin, will retain significant shareholdings through a new holding company formed in conjunction with the acquisition.

Kung Markatta is a market leader in Sweden within the distribution and marketing of ecological and natural products. The company, which was established in Örebro in 1983, has expanded significantly since it was acquired in 2004 by Peter Enberg and his partners. In addition to its own well-renowned range of approximately 150 ecological products under the Kung Markatta trade mark, the company also markets a large portfolio of other brands such as, among others, Alpro, Rice Dream, Yogi Tea, and Green & Black’s.  The company’s turnover in 2012 was approximately SEK 200 million and it currently employs 30 people.

Vinge’s team consisted of partner Daniel Rosvall together with, among others, associates Kristian Ford, Markus Larsson and Maria Dahlin.     

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025